We're Not Very Worried About LTR Pharma's (ASX:LTP) Cash Burn Rate
Mar 18
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedMar 21, 2025
DataAggregated Company Financials
Companies29
- 7D6.9%
- 3M-4.5%
- 1Y-14.7%
- YTDn/a
The Pharma industry is up 3.4% in the last week, with Neuren Pharmaceuticals up 14%. In contrast, the industry has lost 17% in the last 12 months. Looking forward, earnings are forecast to grow by 46% annually.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 21 Mar 2025 | AU$5.0b | AU$1.1b | -AU$289,508,485.00 | 18.9x | -17.2x | 4.7x |
| Sun, 16 Feb 2025 | AU$5.3b | AU$1.0b | -AU$377,002,613.00 | 14.2x | -14.1x | 5.2x |
| Tue, 14 Jan 2025 | AU$5.1b | AU$1.0b | -AU$378,981,112.00 | 12.2x | -13.6x | 5.1x |
| Thu, 12 Dec 2024 | AU$5.7b | AU$1.0b | -AU$378,981,112.00 | 13.1x | -15.1x | 5.6x |
| Sat, 09 Nov 2024 | AU$6.8b | AU$1.0b | -AU$377,703,112.00 | 14.2x | -18x | 6.7x |
| Mon, 07 Oct 2024 | AU$6.6b | AU$1.0b | -AU$377,703,112.00 | 12.9x | -17.5x | 6.5x |
| Wed, 04 Sep 2024 | AU$6.5b | AU$1.0b | -AU$383,620,117.00 | 13.4x | -16.8x | 6.3x |
| Fri, 02 Aug 2024 | AU$6.7b | AU$995.3m | -AU$387,920,108.00 | 11.1x | -17.3x | 6.7x |
| Sun, 30 Jun 2024 | AU$6.6b | AU$995.3m | -AU$387,920,108.00 | 11.5x | -16.9x | 6.6x |
| Tue, 28 May 2024 | AU$6.7b | AU$1.2b | -AU$374,923,684.00 | 14.7x | -17.8x | 5.5x |
| Thu, 25 Apr 2024 | AU$5.5b | AU$1.2b | -AU$374,923,684.00 | 13.2x | -14.6x | 4.5x |
| Sat, 23 Mar 2024 | AU$5.6b | AU$1.2b | -AU$374,923,684.00 | 15.3x | -15x | 4.6x |
| Mon, 19 Feb 2024 | AU$5.3b | AU$892.3m | -AU$534,729,129.00 | 20.4x | -9.9x | 5.9x |
| Wed, 17 Jan 2024 | AU$5.7b | AU$896.3m | -AU$589,604,392.00 | 21.2x | -9.6x | 6.3x |
| Fri, 15 Dec 2023 | AU$4.5b | AU$896.3m | -AU$589,604,392.00 | 17.1x | -7.7x | 5.1x |
| Sun, 12 Nov 2023 | AU$4.0b | AU$893.0m | -AU$595,020,018.00 | 18.1x | -6.7x | 4.5x |
| Tue, 10 Oct 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19x | -6x | 3.9x |
| Thu, 07 Sep 2023 | AU$3.7b | AU$900.3m | -AU$587,952,018.00 | 19.5x | -6.3x | 4.1x |
| Sat, 05 Aug 2023 | AU$4.1b | AU$999.0m | -AU$624,794,303.00 | 21.1x | -6.5x | 4.1x |
| Mon, 03 Jul 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 22.7x | -6.3x | 4x |
| Wed, 31 May 2023 | AU$4.0b | AU$993.2m | -AU$640,306,659.00 | 18.9x | -6.3x | 4.1x |
| Fri, 28 Apr 2023 | AU$4.2b | AU$993.2m | -AU$641,969,868.00 | 19x | -6.6x | 4.3x |
| Sun, 26 Mar 2023 | AU$4.0b | AU$995.9m | -AU$648,651,745.00 | 18.2x | -6.2x | 4.1x |
| Tue, 21 Feb 2023 | AU$3.6b | AU$980.5m | -AU$583,404,566.00 | 16.5x | -6.1x | 3.6x |
| Thu, 19 Jan 2023 | AU$4.1b | AU$948.3m | -AU$544,428,006.00 | 12.9x | -7.6x | 4.3x |
| Sat, 17 Dec 2022 | AU$3.9b | AU$948.3m | -AU$544,428,006.00 | 13.3x | -7.1x | 4.1x |
| Mon, 14 Nov 2022 | AU$4.3b | AU$948.3m | -AU$544,428,005.00 | 12.7x | -8x | 4.6x |
| Wed, 12 Oct 2022 | AU$4.1b | AU$882.1m | -AU$556,645,005.00 | 12.6x | -7.3x | 4.6x |
| Fri, 09 Sep 2022 | AU$4.1b | AU$943.2m | -AU$537,548,829.00 | 12.7x | -7.6x | 4.4x |
| Sun, 07 Aug 2022 | AU$3.9b | AU$819.9m | -AU$339,669,589.00 | 15.6x | -11.6x | 4.8x |
| Tue, 05 Jul 2022 | AU$3.3b | AU$818.2m | -AU$353,932,589.00 | 12.9x | -9.3x | 4x |
| Thu, 02 Jun 2022 | AU$3.9b | AU$818.2m | -AU$353,932,589.00 | 14.8x | -11.1x | 4.8x |
| Sat, 30 Apr 2022 | AU$4.1b | AU$800.9m | -AU$348,637,558.00 | 15.7x | -11.7x | 5.1x |
| Mon, 28 Mar 2022 | AU$4.3b | AU$799.2m | -AU$341,805,125.00 | 18x | -12.7x | 5.4x |
Price to Earnings Ratio
-12.7x
Current Industry PE
- Investors are relatively neutral on the Australian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 9.9% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Australian Pharma compare with similar industries?
| AU Market | 2.33% | |
| Healthcare | 3.31% | |
| Pharma | 6.90% | |
| Pharma | 6.90% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$12.55 | 7.4% +AU$110.5m | -37.9% | PE11.2x | |
| BOT Botanix Pharmaceuticals | AU$0.45 | 8.4% +AU$63.9m | 125.0% | PS397x | |
| CU6 Clarity Pharmaceuticals | AU$2.78 | 5.7% +AU$48.2m | -2.5% | PS82.9x | |
| AGN Argenica Therapeutics | AU$0.86 | 14.7% +AU$14.1m | 50.9% | PS35.8x | |
| RCE Recce Pharmaceuticals | AU$0.41 | 15.7% +AU$12.8m | -12.0% | PS9.8x |
